The report analyzes and forecasts the scleroderma therapeutics and diagnostics market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of scleroderma therapeutics and diagnostics, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major scleroderma therapeutics and diagnostics companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of scleroderma therapeutics and diagnostics upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of scleroderma therapeutics and diagnostics and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global scleroderma therapeutics and diagnostics market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the scleroderma therapeutics and diagnostics market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of scleroderma therapeutics and diagnostics market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Actelion Pharmaceuticals, Inc., Boehringer Ingelheim, Bayer AG, Cytori Therapeutics, Inc., Corbus Pharmaceutical Holdings Inc, Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and Sanofi are some of the key players operating in the global scleroderma diagnostics and therapeutics market.
The global scleroderma diagnostics and therapeutics market is segmented as follows:
Global Scleroderma Therapeutics Market, by Drug Class
Global Scleroderma Therapeutics Market, by Indication
Global Scleroderma Diagnostics Market, by Test Type
Global Scleroderma Diagnostics and Therapeutics Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Scleroderma Diagnostics and Therapeutics Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Drug Class Definition
4.1.2. Industry Developments
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecasts, 2017–2026
4.5. Scleroderma Diagnostics and Therapeutics Market Outlook
4.6. Scleroderma : Overview of Clinical Trials
Chapter 5. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Indication
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
5.3.1. Localized
5.3.2. Systemic
5.4. Market Attractiveness Analysis, by Indication, 2018
5.5. Key Trends and Developments
Chapter 6. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class
6.3.1. Corticosteroids
6.3.2. Immunosuppressive Agents
6.3.3. Endothelin receptor antagonists
6.3.4. Calcium Channel Blockers
6.3.5. PDE-5 Inhibitors
6.3.6. Chelating Agents
6.3.7. Prostacyclin analogues
6.3.8. Others
6.4. Market Attractiveness Analysis, by Drug Class, 2018
6.5. Key Trends and Developments
Chapter 7. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4. Market Attractiveness Analysis, by Region, 2018
7.5. Key Trends
Chapter 8. North America Scleroderma Therapeutics Market Analysis and Forecast
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Indication
8.3.1. Localized
8.3.2. Systemic
8.4. Market Size (US$ Mn) Forecast, by Drug Class
8.4.1. Corticosteroids
8.4.2. Immunosuppressive Agents
8.4.3. Endothelin receptor antagonists
8.4.4. Calcium Channel Blockers
8.4.5. PDE-5 Inhibitors
8.4.6. Chelating Agents
8.4.7. Prostacyclin analogues
8.4.8. Others
8.5. Market Size (US$ Mn) Forecast, by Country
8.5.1. U.S.
8.5.2. Canada
8.6. Market Attractiveness Analysis, by Indication, 2018
8.7. Market Attractiveness Analysis, by Drug Class, 2018
8.8. Key Trends
Chapter 9. Europe Scleroderma Therapeutics Market Analysis and Forecast
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Indication
9.3.1. Localized
9.3.2. Systemic
9.4. Market Size (US$ Mn) Forecast, by Drug Class
9.4.1. Corticosteroids
9.4.2. Immunosuppressive Agents
9.4.3. Endothelin receptor antagonists
9.4.4. Calcium Channel Blockers
9.4.5. PDE-5 Inhibitors
9.4.6. Chelating Agents
9.4.7. Prostacyclin analogues
9.4.8. Others
9.5. Market Size (US$ Mn) Forecast, by Country
9.5.1. U.K.
9.5.2. Germany
9.5.3. France
9.5.4. Rest of Europe
9.6. Market Attractiveness Analysis, by Indication 2018
9.7. Market Attractiveness Analysis, by Drug Class, 2018
9.8. Key Trends
Chapter 10. Asia Pacific Scleroderma Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Introduction
10.3. Market Size (US$ Mn) Forecast, by Indication
10.3.1. Localized
10.3.2. Systemic
10.4. Market Size (US$ Mn) Forecast, by Drug Class
10.4.1. Corticosteroids
10.4.2. Immunosuppressive Agents
10.4.3. Endothelin receptor antagonists
10.4.4. Calcium Channel Blockers
10.4.5. PDE-5 Inhibitors
10.4.6. Chelating Agents
10.4.7. Prostacyclin analogues
10.4.8. Others
10.5. Market Size (US$ Mn) Forecast, by Country
10.5.1. China
10.5.2. India
10.5.3. Japan
10.5.4. Rest of Asia Pacific
10.6. Market Attractiveness Analysis, by Indication, 2018
10.7. Market Attractiveness Analysis, by Drug Class, 2018
10.8. Key Trends
Chapter 11. Latin America Scleroderma Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Introduction
11.3. Market Size (US$ Mn) Forecast, by Product
11.3.1. Localized
11.3.2. Systemic
11.4. Market Size (US$ Mn) Forecast, by Distribution Channel
11.4.1. Corticosteroids
11.4.2. Immunosuppressive Agents
11.4.3. Endothelin receptor antagonists
11.4.4. Calcium Channel Blockers
11.4.5. PDE-5 Inhibitors
11.4.6. Chelating Agents
11.4.7. Prostacyclin analogues
11.4.8. Others
11.5. Market Size (US$ Mn) Forecast, by Country
11.5.1. Brazil
11.5.2. Mexico
11.5.3. Rest of Latin America
11.6. Market Attractiveness Analysis, by Indication, 2018
11.7. Market Attractiveness Analysis, by Drug Class, 2018
11.8. Key Trends
Chapter 12. Middle East & Africa Radiodermatitis Market Analysis and Forecast
12.1. Key Findings
12.2. Introduction
12.3. Market Size (US$ Mn) Forecast, by Indication
12.3.1. Localized
12.3.2. Systemic
12.4. Market Size (US$ Mn) Forecast, by Drug Class
12.4.1. Corticosteroids
2.4.2. Immunosuppressive Agents
12.4.3. Endothelin receptor antagonists
12.4.4. Calcium Channel Blockers
12.4.5. PDE-5 Inhibitors
12.4.6. Chelating Agents
12.4.7. Prostacyclin analogues
12.4.8. Others
12.5. Market Size (US$ Mn) Forecast, by Country
12.5.1. UAE
12.5.2. South Africa
12.5.3. Rest of Middle East & Africa
12.6. Market Attractiveness Analysis, by Indication, 2018
12.7. Market Attractiveness Analysis, by Drug Class, 2018
12.8. Key Trends
Chapter 13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profiles
13.2.1. Actelion Pharmaceuticals, Inc.
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Financial Overview
13.2.1.3. Product Portfolio
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.2. Bayer AG
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Financial Overview
13.2.2.3. Product Portfolio
13.2.2.4. SWOT Analysis
13.2.2.5. Strategic Overview
13.2.3. Boehringer Ingelheim
13.2.3.1. Company Overview (HQ, business segments, employee strength)
13.2.3.2. Product Portfolio
13.2.3.3. SWOT Analysis
13.2.3.4. Financial Overview
13.2.3.5. Strategic Overview
13.2.4. Corbus Pharmaceutical Holdings, Inc.
13.2.4.1. Company Overview (HQ, business segments, employee strength)
13.2.4.2. Product Portfolio
13.2.4.3. SWOT Analysis
13.2.4.4. Strategic Overview
13.2.4.5. Key Developments
13.2.5. Cumberland Pharmaceuticals Inc.
13.2.5.1. Company Overview (HQ, business segments, employee strength)
13.2.5.2. Financial Overview
13.2.5.3. Product Portfolio
13.2.5.4. SWOT Analysis
13.2.5.5. Strategic Overview
13.2.6. Cytori Therapeutics, Inc.
13.2.6.1. Company Overview (HQ, business segments, employee strength)
13.2.6.2. Product Portfolio
13.2.6.3. SWOT Analysis
13.2.6.4. Financial Overview
13.2.6.5. Strategic Overview
13.2.7. F. Hoffmann La Roche Ltd.
13.2.7.1. Company Overview (HQ, business segments, employee strength)
13.2.7.2. Financial Overview
13.2.7.3. Product Portfolio
13.2.7.4. SWOT Analysis
13.2.7.5. Strategic Overview
13.2.8. Gilead Sciences, Inc.
13.2.8.1. Company Overview (HQ, business segments, employee strength)
13.2.8.2. Financial Overview
13.2.8.3. Product Portfolio
13.2.8.4. SWOT Analysis
13.2.8.5. Strategic Overview
13.2.9. Merck KGaA
13.2.9.1. Company Overview (HQ, business segments, employee strength)
13.2.9.2. Product Portfolio
13.2.9.3. Financial Overview
13.2.9.4. SWOT Analysis
13.2.9.5. Strategic Overview
13.2.10. Pfizer, Inc.
13.2.10.1. Company Overview (HQ, business segments, employee strength)
13.2.10.2. Product Portfolio
13.2.10.3. Financial Overview
13.2.10.4. SWOT Analysis
13.2.10.5. Strategic Overview
13.2.11. Sanofi
13.2.11.1. Company Overview (HQ, business segments, employee strength)
13.2.11.2. Product Portfolio
13.2.11.3. Financial Overview
13.2.11.4. SWOT Analysis
13.2.11.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers